11-18-2021, 12:07 AM
The article says it is about to enter a small-scale clinical trial, so it must already have succeeded in preclinical trials. The first patient will receive it in Jan 2022. The control group of 13 will receive placebos, while the other group of 13 will receive the vaccine. Interesting to read that the vaccine group will receive varying doses, which suggests they're trying to speed up the trial process by blending Phase 1 & 2.


